BMO Capital Downgrades Pfizer (PFE) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Argus Downgrades Pfizer (PFE) to Hold
November 2, 2016 7:54 AM EDTArgus downgraded Pfizer (NYSE: PFE) from Buy to Hold on a weaker outlook.
The analyst no longer expect PFE to achieve their former target price of $39 given recent pipeline setbacks, prospects for increased competition, and managements decision to shelve its business separation... More
Pfizer (PFE) Misses Q3 EPS by 1c
November 1, 2016 6:46 AM EDTPfizer (NYSE: PFE) reported Q3 EPS of $0.61, $0.01 worse than the analyst estimate of $0.62. Revenue for the quarter came in at $13.05 billion versus the consensus estimate of $13.05 billion.
Prevnar revenue was $1.54 billion, versus $1.46 billion expectedIbrance revenue was $550 million, versus $548.4 million expected.EXECUTIVE COMMENTARY
Ian Read, Chairman and Chief Executive Officer, stated, Our business continues to perform well as demonstrated by the quarters financial results. Our Innovative Health business executed strongly behind the latest product launches, and our two recent acquisitions -- Medivation and Anacor -- are providing new near-term... More
